SCM Life Science Obtains US Patent for Pharmaceutical Composition for Immune Disease Treatment
[Asia Economy Reporter Kim Ji-hee] SCM Life Science announced on the 21st that it has obtained a U.S. patent for a pharmaceutical composition that induces the binding of mesenchymal stem cells and regulatory T cells, which can be used for the prevention and treatment of immune diseases.
The patented pharmaceutical composition is mesenchymal stem cells overexpressing 'ICOSL'. When an immune response occurs in the body, the protein ICOSL is overexpressed in mesenchymal stem cells. At the same time, the expression of the ICOS protein, a receptor on the surface of regulatory T cells that binds to ICOSL and performs immune suppression functions in the body, also increases.
Regulatory T cells regulate the immune response of T cells, which are representative immune cells in the body. When the interaction between mesenchymal stem cells and regulatory T cells increases through the binding of ICOSL and the ICOS receptor, the secretion of a cytokine called IL-10 from regulatory T cells is promoted. This effectively regulates the immune response of abnormally increased CD4+ T cells.
An SCM Life Science official stated, "Mesenchymal stem cells overexpressing ICOSL can be used to treat various inflammatory or autoimmune diseases," adding, "This patent can be applied to the treatment of various autoimmune diseases such as rheumatoid arthritis, alopecia areata, colitis, and lupus."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The patent has already been registered in countries including Korea, China, Japan, Australia, and Russia. However, the company explained that the U.S. patent registration is significant as it provides a technical and legal foundation for SCM Life Science’s research and development and market entry in the United States. An SCM Life Science official emphasized, "Through this U.S. patent registration, we have been able to further strengthen the acquisition of core intellectual property rights for global commercialization as a specialized cell therapy development company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
